1-5 of 5
Francesco Fiorentini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

Barbara Valsasina, Paolo Orsini, Michele Caruso, Clara Albanese, Antonella Ciavolella, Ulisse Cucchi, Ivan Fraietta, Nicola Melillo, Francesco Fiorentini, Simona Rizzi, Matteo Salsa, Antonella Isacchi, Fabio Gasparri
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1465–1478.
https://doi.org/10.1158/1535-7163.MCT-23-0315
Published: 01 December 2023
View article titled, Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
Open the PDF for Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies in another window
Includes: Supplementary data
Journal Articles

NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

Barbara Valsasina, Italo Beria, Cristina Alli, Rachele Alzani, Nilla Avanzi, Dario Ballinari, Paolo Cappella, Michele Caruso, Alessia Casolaro, Antonella Ciavolella, Ulisse Cucchi, Anna De Ponti, Eduard Felder, Francesco Fiorentini, Arturo Galvani, Laura M. Gianellini, Maria L. Giorgini, Antonella Isacchi, Jaqueline Lansen, Enrico Pesenti, Simona Rizzi, Maurizio Rocchetti, Francesco Sola, Jürgen Moll
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (4): 1006–1016.
https://doi.org/10.1158/1535-7163.MCT-11-0765
Published: 08 April 2012
View article titled, NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
Open the PDF for NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy

Clara Albanese, Rachele Alzani, Nadia Amboldi, Nilla Avanzi, Dario Ballinari, Maria Gabriella Brasca, Claudio Festuccia, Francesco Fiorentini, Giuseppe Locatelli, Wilma Pastori, Veronica Patton, Fulvia Roletto, Francesco Colotta, Arturo Galvani, Antonella Isacchi, Jurgen Moll, Enrico Pesenti, Ciro Mercurio, Marina Ciomei
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (8): 2243–2254.
https://doi.org/10.1158/1535-7163.MCT-10-0190
Published: 09 August 2010
View article titled, Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
Open the PDF for Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy in another window
Includes: Supplementary data
Journal Articles

Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study

Giuseppe Locatelli, Roberta Bosotti, Marina Ciomei, Maria G. Brasca, Raffaele Calogero, Ciro Mercurio, Francesco Fiorentini, Matteo Bertolotti, Emanuela Scacheri, Angela Scaburri, Arturo Galvani, Enrico Pesenti, Thierry De Baere, Jean-Charles Soria, Vladimir Lazar, Antonella Isacchi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (5): 1265–1273.
https://doi.org/10.1158/1535-7163.MCT-09-1163
Published: 09 May 2010
View article titled, Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study
Open the PDF for Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study in another window
Includes: Supplementary data
Journal Articles

Abstract PR-3: Antitumor efficacy on glioma models of the dual CDK/TRKA inhibitor PHA‐848125, able to cross the blood brain barrier

Clara Albanese, Wilma Pastori, Giuseppe Locatelli, Rachele Alzani, Francesco Fiorentini, Claudio Festuccia, Enrico Pesenti, Arturo Galvani, Antonella Isacchi, Ciro Mercurio, Maria Gabriella Brasca, Marina Ciomei
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): PR-3.
https://doi.org/10.1158/1535-7163.TARG-09-PR-3
Published: 10 December 2009
View article titled, Abstract PR-3: Antitumor efficacy on glioma models of the dual CDK/TRKA inhibitor PHA‐848125, able to cross the blood brain barrier